PT  - JOURNAL ARTICLE
AU  - Grishma Shrestha
AU  - Racheal Githumbi
AU  - Bryce Oslanski
AU  - Nadia Lachman
AU  - Daria Venkova
AU  - Ben Montgomery
AU  - Cora Pieron
AU  - John Dennis
AU  - Candice L Bjornson
AU  - Julie Jarand
AU  - Michael Parkins
AU  - Ashten Langevin
AU  - Kate Skolnik
AU  - Lori Fairservice
AU  - Clare Smith
AU  - Francis Green
AU  - Mark Montgomery
TI  - A Phase IIa Open Label Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 Administered by Nebulization in Subjects with Cystic Fibrosis Lung Disease
AID  - 10.1101/2021.12.10.21266937
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.10.21266937
4099  - http://medrxiv.org/content/early/2021/12/13/2021.12.10.21266937.short
4100  - http://medrxiv.org/content/early/2021/12/13/2021.12.10.21266937.full
AB  - Rationale There are approximately 35,000 people with Cystic Fibrosis (CF) in North America. This condition is characterized by impaired airway clearance resulting in chronic infection and bronchiectasis. Current airway clearance treatments include nebulized hypertonic saline and Recombinant Human DNase, which may be limited by bronchospasm and cost, respectively. S-1226, a novel biophysical therapeutic agent combines carbon dioxide (CO2) enriched air (a bronchodilator) with nebulized perflubron (PFOB), (a synthetic surfactant). They act synergistically to open airways, enhance mucus clearance, and increase blood oxygenation. We report preliminary results from a Phase II clinical trial.Methods An open label, single-center, Phase IIa study of subjects (≥14 years) with mild-moderate (FEV1 40-80%) CF lung disease treated with multiple ascending doses of S-1226 (week one), followed by the highest tolerated dose for 5 consecutive days (week two). Each dose of S-1226 comprised three successive treatments of 3mL of perflubron nebulized (Circulaire®II) for two-minutes with CO2 concentrations ranging from 4 to 12%. The oxygen concentration was maintained at ambient levels. Treatments were administered twice daily. Efficacy measurements included spirometry, lung clearance index (LCI), lung volumes, blood oxygenation (SPO2), sputum weight and the respiratory domain of quality of life (QOL) questionnaire (CFQ-R). Safety included adverse event (AE) and tolerance monitoring, vital signs, and assessment of end-tidal CO2.Results We report preliminary data on safety and efficacy for six CF subjects. All subjects tolerated all doses of S-1226. There were 5 reported AEs in 3 subjects. All were mild and resolved spontaneously. End-tidal CO2 immediately after treatment was comparable to baseline. SpO2 (baseline 91-95%) rapidly improved in all subjects with treatment. Five of six subjects had improvements in their LCI. Three subjects that were compliant in collecting mucus showed increases of 14%, 29% and 64% over baseline. Percent predicted FEV1 response was variable, decreasing initially with return to pre-treatment values at two weeks. Four of the six subjects reported improvements in CFQ-R scores, three of which showed a clinically important difference (> 4 points). An important observation was that S-1226 controlled irritant (but not productive) cough in all five subjects and at all concentrations of S-1226.Conclusions All doses of S-1226 were safe and well tolerated. Treatments with up to 12% extrinsic CO2 over short periods of time did not result in an elevation of end-tidal CO2. The preliminary efficacy results, including overall improved oxygen saturation, CFQ-R scores, increased expectorated mucus and LCI values provide evidence for potential beneficial effects of S-1226 for CF lung disease but require larger trials and longer-term treatments to fully assess efficacy in CF.Competing Interest StatementOf the investigators, only one (Dr. Francis Green) has proprietary interests in the product under study. Dr. Green's proprietary interest is that he is a co-inventor of the drug technology, holds relevant patents and is a co-founder of the company SolAeroMed Inc. that provided the drug for the study. Dr. Green is also a Board member of SolAeroMed and has equity in the company. The company is a spinoff from the University of Calgary through Universities Technologies International (UTI), now called Innovate Calgary. The University of Calgary is a major shareholder in SolAeroMed. The Principal Investigator (Dr. Mark Montgomery) is in discussion with SolAeroMed regarding participation in further development of S-1226. Additionally, Dr John Dennis is the Chief Executive Officer (CEO) of SolAeroMed Inc. Other investigators and collaborators have no conflicts of interest to declare.Clinical TrialNCT03903913Funding StatementThis clinical trial was funded in part by SolAeroMed Inc. SolAeroMed Inc. also provided the drug and delivery systems.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Conjoint Health Research Ethics Board (CHREB) of University of Calgary gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis trial has been registered at clinical trials.gov NCT03903913. Some data generated or analyzed during this study is included in the Supplemental materials to support the findings of this study. Additional data and study protocol are available upon reasonable request with the permission of SolAeroMed Inc. Please be aware that some restrictions apply to the availability of these data since they were used under license for the current study and are not publicly available. https://www.solaeromed.com/